Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that patient enrollment in its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached the halfway mark. The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination. Preliminary imaging data have shown encouraging signal in acute MS lesions and potential sensitivity to gray matter lesions, which the company believes could enhance development of MS therapies including its investigational candidate Lucid-MS.
The company submitted an Investigational New Drug (IND) application for a Phase 2 trial of Lucid-MS to the FDA in March 2026. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The imaging study, conducted in collaboration with Massachusetts General Hospital, aims to provide a non-invasive method to visualize demyelination, which could accelerate clinical development and potentially serve as a biomarker for treatment response.
Quantum BioPharma is a biopharmaceutical company focused on neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is developing Lucid-MS for multiple sclerosis. The company also retains a 19.84% ownership stake in Unbuzzd Wellness Inc. and receives royalty payments from sales of UNBUZZD™. For more information, visit the company's newsroom at https://ibn.fm/QNTM.
This milestone is significant as it brings the study closer to completion, potentially providing critical data to support the development of Lucid-MS and other MS therapies. The ability to directly visualize demyelination could improve diagnosis and monitoring of MS, a disease affecting millions worldwide. The collaboration with Massachusetts General Hospital, a leading research institution, adds credibility to the study's findings.
Forward-looking statements in this article involve risks and uncertainties. For more details, see the full terms of use and disclaimers at http://IBN.fm/Disclaimer.